Nucleus-Targeted Organoiridium–Albumin Conjugate for Photodynamic Cancer Therapy

Pingyu Zhang, Huaiyi Huang*, Samya Banerjee, Guy J. Clarkson, Chen Ge, Cinzia Imberti, Peter J. Sadler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

145 Citations (Scopus)

Abstract

An organoiridium–albumin bioconjugate (Ir1-HSA) was synthesized by reaction of a pendant maleimide ligand with human serum albumin. The phosphorescence of Ir1-HSA was enhanced significantly compared to parent complex Ir1. The long phosphorescence lifetime and high 1 O 2 quantum yield of Ir1-HSA are highly favorable properties for photodynamic therapy. Ir1-HSA mainly accumulated in the nucleus of living cancer cells and showed remarkable photocytotoxicity against a range of cancer cell lines and tumor spheroids (light IC 50 ; 0.8–5 μm, photo-cytotoxicity index PI=40–60), while remaining non-toxic to normal cells and normal cell spheroids, even after photo-irradiation. This nucleus-targeting organoiridium-albumin is a strong candidate photosensitizer for anticancer photodynamic therapy.

Original languageEnglish
Pages (from-to)2350-2354
Number of pages5
JournalAngewandte Chemie - International Edition
Volume58
Issue number8
DOIs
Publication statusPublished - 18 Feb 2019

Keywords

  • albumin
  • organoiridium
  • photodynamic therapy
  • photosensitizers

Fingerprint

Dive into the research topics of 'Nucleus-Targeted Organoiridium–Albumin Conjugate for Photodynamic Cancer Therapy'. Together they form a unique fingerprint.

Cite this